Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for BioCorRx (BICX) over the last 17 years, with Q3 2025 value amounting to -$634447.0.

  • BioCorRx's Cash from Operations fell 7744.63% to -$634447.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 2276.48%. This contributed to the annual value of -$1.1 million for FY2024, which is 4084.8% up from last year.
  • Per BioCorRx's latest filing, its Cash from Operations stood at -$634447.0 for Q3 2025, which was down 7744.63% from -$126499.0 recorded in Q2 2025.
  • In the past 5 years, BioCorRx's Cash from Operations registered a high of -$126499.0 during Q2 2025, and its lowest value of -$1.3 million during Q2 2021.
  • Its 5-year average for Cash from Operations is -$525238.7, with a median of -$449576.0 in 2022.
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 14793.18% in 2021, then soared by 7371.86% in 2022.
  • Over the past 5 years, BioCorRx's Cash from Operations (Quarter) stood at -$647624.0 in 2021, then surged by 30.58% to -$449576.0 in 2022, then fell by 18.74% to -$533836.0 in 2023, then soared by 53.7% to -$247170.0 in 2024, then tumbled by 156.68% to -$634447.0 in 2025.
  • Its last three reported values are -$634447.0 in Q3 2025, -$126499.0 for Q2 2025, and -$689623.0 during Q1 2025.